Nisha Bansal1, Ronit Katz2, Lorien Dalrymple3, Ian de Boer2, Christopher DeFilippi4, Bryan Kestenbaum2, Meyeon Park5, Mark Sarnak6, Stephen Seliger7, Michael Shlipak8. 1. Kidney Research Institute, Division of Nephrology, University of Washington, Seattle, Washington; nbansal@nephrology.washington.edu. 2. Kidney Research Institute, Division of Nephrology, University of Washington, Seattle, Washington; 3. Division of Nephrology, University of California, Davis, Sacramento, California; 4. Divisions of Cardiology and. 5. Division of Nephrology and. 6. Division of Nephrology, Tufts Medical Center, Boston, Massachusetts; and. 7. Nephrology, University of Maryland, Baltimore, Maryland; 8. Departments of Medicine, Epidemiology, and Biostatistics, University of California, San Francisco, California; Division of General Internal Medicine, San Francisco Veterans Affair Medical Center, San Francisco, California.
Abstract
BACKGROUND AND OBJECTIVES: Elevations in N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T are associated with poor cardiovascular outcomes. Whether elevations in these cardiac biomarkers are associated with decline in kidney function was evaluated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: N-terminal pro-B-type natriuretic peptide and troponin T were measured at baseline in 3752 participants free of heart failure in the Cardiovascular Health Study. eGFR was determined from the Chronic Kidney Disease Epidemiology Collaboration equation using serum cystatin C. Rapid decline in kidney function was defined as decline in serum cystatin C eGFR≥30%, and incident CKD was defined as the onset of serum cystatin C eGFR<60 among those without CKD at baseline (n=2786). Cox regression models were used to examine the associations of each biomarker with kidney function decline adjusting for demographics, baseline serum cystatin C eGFR, diabetes, and other CKD risk factors. RESULTS: In total, 503 participants had rapid decline in serum cystatin C eGFR over a mean follow-up time of 6.41 (1.81) years, and 685 participants developed incident CKD over a mean follow-up time of 6.41 (1.74) years. Participants in the highest quartile of N-terminal pro-B-type natriuretic peptide (>237 pg/ml) had an 67% higher risk of rapid decline and 38% higher adjusted risk of incident CKD compared with participants in the lowest quartile (adjusted hazard ratio for serum cystatin C eGFR rapid decline, 1.67; 95% confidence interval, 1.25 to 2.23; hazard ratio for incident CKD, 1.38; 95% confidence interval, 1.08 to 1.76). Participants in the highest category of troponin T (>10.58 pg/ml) had 80% greater risk of rapid decline compared with participants in the lowest category (adjusted hazard ratio, 1.80; 95% confidence interval, 1.35 to 2.40). The association of troponin T with incident CKD was not statistically significant (hazard ratio, 1.17; 95% confidence interval, 0.92 to 1.50). CONCLUSIONS: Elevated N-terminal pro-B-type natriuretic peptide and troponin T are associated with rapid decline of kidney function and incident CKD. Additional studies are needed to evaluate the mechanisms that may explain this association.
BACKGROUND AND OBJECTIVES: Elevations in N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T are associated with poor cardiovascular outcomes. Whether elevations in these cardiac biomarkers are associated with decline in kidney function was evaluated. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: N-terminal pro-B-type natriuretic peptide and troponin T were measured at baseline in 3752 participants free of heart failure in the Cardiovascular Health Study. eGFR was determined from the Chronic Kidney Disease Epidemiology Collaboration equation using serum cystatin C. Rapid decline in kidney function was defined as decline in serum cystatin CeGFR≥30%, and incident CKD was defined as the onset of serum cystatin CeGFR<60 among those without CKD at baseline (n=2786). Cox regression models were used to examine the associations of each biomarker with kidney function decline adjusting for demographics, baseline serum cystatin CeGFR, diabetes, and other CKD risk factors. RESULTS: In total, 503 participants had rapid decline in serum cystatin CeGFR over a mean follow-up time of 6.41 (1.81) years, and 685 participants developed incident CKD over a mean follow-up time of 6.41 (1.74) years. Participants in the highest quartile of N-terminal pro-B-type natriuretic peptide (>237 pg/ml) had an 67% higher risk of rapid decline and 38% higher adjusted risk of incident CKD compared with participants in the lowest quartile (adjusted hazard ratio for serum cystatin CeGFR rapid decline, 1.67; 95% confidence interval, 1.25 to 2.23; hazard ratio for incident CKD, 1.38; 95% confidence interval, 1.08 to 1.76). Participants in the highest category of troponin T (>10.58 pg/ml) had 80% greater risk of rapid decline compared with participants in the lowest category (adjusted hazard ratio, 1.80; 95% confidence interval, 1.35 to 2.40). The association of troponin T with incident CKD was not statistically significant (hazard ratio, 1.17; 95% confidence interval, 0.92 to 1.50). CONCLUSIONS: Elevated N-terminal pro-B-type natriuretic peptide and troponin T are associated with rapid decline of kidney function and incident CKD. Additional studies are needed to evaluate the mechanisms that may explain this association.
Authors: Lori B Daniels; Gail A Laughlin; Paul Clopton; Alan S Maisel; Elizabeth Barrett-Connor Journal: J Am Coll Cardiol Date: 2008-08-05 Impact factor: 24.094
Authors: Wilfried Mullens; Zuheir Abrahams; Gary S Francis; George Sokos; David O Taylor; Randall C Starling; James B Young; W H Wilson Tang Journal: J Am Coll Cardiol Date: 2009-02-17 Impact factor: 24.094
Authors: Roland R J van Kimmenade; James L Januzzi; Jaap A Bakker; Alphonse J Houben; Roger Rennenberg; Abraham A Kroon; Harry J G M Crijns; Marja P van Dieijen-Visser; Peter W de Leeuw; Yigal M Pinto Journal: J Am Coll Cardiol Date: 2009-03-10 Impact factor: 24.094
Authors: Björn Zethelius; Lars Berglund; Johan Sundström; Erik Ingelsson; Samar Basu; Anders Larsson; Per Venge; Johan Arnlöv Journal: N Engl J Med Date: 2008-05-15 Impact factor: 91.245
Authors: Michael G Shlipak; Ronit Katz; Bryan Kestenbaum; Linda F Fried; David Siscovick; Mark J Sarnak Journal: Atherosclerosis Date: 2008-08-26 Impact factor: 5.162
Authors: Michael G Shlipak; Ronit Katz; Bryan Kestenbaum; Linda F Fried; Anne B Newman; David S Siscovick; Lesley Stevens; Mark J Sarnak Journal: Am J Nephrol Date: 2009-04-07 Impact factor: 3.754
Authors: Dena E Rifkin; Michael G Shlipak; Ronit Katz; Linda F Fried; David Siscovick; Michel Chonchol; Anne B Newman; Mark J Sarnak Journal: Arch Intern Med Date: 2008-11-10
Authors: Leila R Zelnick; Ronit Katz; Bessie A Young; Adolfo Correa; Bryan R Kestenbaum; Ian H de Boer; Nisha Bansal Journal: Am J Kidney Dis Date: 2017-01-28 Impact factor: 8.860
Authors: Junichi Ishigami; Yuhree Kim; Yingying Sang; Steven P Menez; Morgan E Grams; Hicham Skali; Amil M Shah; Ron C Hoogeveen; Elizabeth Selvin; Scott D Solomon; Christie M Ballantyne; Josef Coresh; Kunihiro Matsushita Journal: Clin Chem Date: 2021-01-08 Impact factor: 8.327
Authors: Nisha Bansal; Leila Zelnick; Michael G Shlipak; Amanda Anderson; Robert Christenson; Rajat Deo; Christopher deFilippi; Harold Feldman; James Lash; Jiang He; John Kusek; Bonnie Ky; Stephen Seliger; Elsayed Z Soliman; Alan S Go Journal: Clin Chem Date: 2019-10-02 Impact factor: 8.327
Authors: LaTonya J Hickson; Andrew D Rule; Kenneth R Butler; Gary L Schwartz; Allan S Jaffe; Adam C Bartley; Thomas H Mosley; Stephen T Turner Journal: Mayo Clin Proc Date: 2015-10-19 Impact factor: 7.616
Authors: Amanda H Anderson; Dawei Xie; Xue Wang; Robin L Baudier; Paula Orlandi; Lawrence J Appel; Laura M Dember; Jiang He; John W Kusek; James P Lash; Sankar D Navaneethan; Akinlolu Ojo; Mahboob Rahman; Jason Roy; Julia J Scialla; James H Sondheimer; Susan P Steigerwalt; F Perry Wilson; Myles Wolf; Harold I Feldman Journal: Am J Kidney Dis Date: 2020-08-28 Impact factor: 8.860
Authors: Gwen M Bernacki; Cara L McDermott; Daniel D Matlock; Ann M O'Hare; Lyndia Brumback; Nisha Bansal; James N Kirkpatrick; Ruth A Engelberg; Jared Randall Curtis Journal: J Pain Symptom Manage Date: 2021-08-04 Impact factor: 3.612